Market research
GLPG.AS Galapagos NV
AS EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 2B
- P/E ratio
- 3.18
- Analyst target
- 30.15
- Dividend yield
- Not available
- Beta
- 0.12
Profile
Company facts
- Exchange
- AS
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- BE0003818359
- Market cap
- 2B
- P/E ratio
- 3.18
- Analyst target
- 30.15
- Dividend yield
- Not available
- Beta
- 0.12
About
About Galapagos NV
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the GLPG.AS discussion.
5 years, 5 months ago
Galapagos NV is currently in a long term downtrend where the price is trading 29.9% below its 200 day moving average.
From a valuation standpoint, the stock is 243.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 9.2.
Galapagos NV's total revenue rose by 0.7% to $144M since the same quarter in the previous year.
Its net income has increased by 49.9% to $-58M since the same quarter in the previous year.
Finally, its free cash flow grew by 49.9% to $-83M since the same quarter in the previous year.
Based on the above factors, Galapagos NV gets an overall score of 3/5.